Novo Nordisk's CagriSema Receives FDA Approval As Global Weight-Loss Drug Market Approaches $150bn

The US Food and Drug Administration formally approved Novo Nordisk's CagriSema — a fixed-ratio combination of cagrilintide and semaglutide — for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity on Thursday, clearing the Danish pharmaceutical company's next-generation GLP-1-and-amylin combination therapy and substantially extending its leadership position in the global obesity-treatment market that has been the most commercially-dynamic pharmaceutical sector of the 2023–2026 period.

The CagriSema approval profile, articulated in the FDA's formal label released on Thursday, is anchored on the REDEFINE 1 trial's principal efficacy finding: a mean body-weight reduction of 22.7% at 68 weeks in the CagriSema arm versus 2.3% in the placebo arm — a magnitude of weight loss that substantially exceeds the 14.9% mean weight reduction delivered by semaglutide 2.4mg (Wegovy) in its pivotal STEP 1 trial, and approaches the weight-loss outcomes previously achievable only through bariatric surgery. The cardiovascular-outcomes dataset, drawn from the REDEFINE 2 trial, demonstrated a 28% reduction in major adverse cardiovascular events versus placebo — a clinically meaningful differentiation that Novo Nordisk expects to leverage across the payer-coverage and prescribing-authority negotiation cycle.

The commercial context is meaningful. CagriSema's approval positions Novo Nordisk with the most efficacious approved weekly-injection obesity therapy in the US market — a positioning that is expected to generate peak annual sales estimates ranging from $18 billion to $24 billion across the consensus analyst community, substantially exceeding the current Wegovy peak-sales trajectory and broadly comparable to Ozempic's aggregate annual sales base. The competitive landscape remains active: Eli Lilly's tirzepatide (Zepbound) — which demonstrated 20.9% mean weight reduction in its pivotal SURMOUNT-1 trial — remains Novo Nordisk's principal competitor, with both companies progressively investing in manufacturing-capacity expansion to address the supply constraints that have characterised the obesity-drug market since 2023.

The healthcare-system-and-payer context is meaningful. The CagriSema approval arrives at a point where the obesity-drug reimbursement landscape in the US is substantively broader than the pre-Wegovy baseline — with Medicare Part D coverage for anti-obesity medications having been formally enacted through the Treat and Reduce Obesity Act provisions included in the December 2024 fiscal package, and commercial-payer coverage having progressively expanded across the post-2023 window as the cardiovascular-outcomes evidence base matured. The CagriSema launch pricing — expected to be set in the $1,400–1,600 per month range, broadly consistent with the current Wegovy and Zepbound net-price framework — will be the principal commercial variable across the launch trajectory.

For investors and operators across the global pharmaceutical and healthcare sectors, the Thursday FDA CagriSema approval is the clearest single confirmation that the obesity-drug therapeutic-area continues to compound toward the $150 billion global annual-sales threshold that the consensus long-term modelling has been projecting — and that Novo Nordisk's pipeline execution has maintained the next-generation innovation cadence required to sustain its competitive positioning against Eli Lilly and the broader GLP-1 developer pipeline. The principal forward variable through the rest of the year is the rate of payer-coverage expansion and manufacturing-capacity ramp for CagriSema — which will together substantially determine the speed at which the approval translates into the peak-sales trajectory the market has been pricing.